By Iris Kulbatski — 2020
Psychedelic drugs like psilocybin are being tested to treat mental illness. They're also expanding our understanding about human consciousness.
Read on www.discovermagazine.com
CLEAR ALL
As Western medicine brings psychedelics into mainstream use, a growing movement is innovating new business models grounded in reciprocity and inclusion.
1
Ganzflicker is known to elicit the experience of anomalous sensory information in the external environment, called pseudo-hallucinations.
In mice and one person, scientists were able to reproduce the altered state often associated with ketamine by inducing certain brain cells to fire together in a slow, rhythmic fashion.
In the last two decades, researchers have started to reexamine psychedelics for their therapeutic potential. Though initial results seem promising, the research has a significant shortcoming: the lack of racial and ethnic diversity among research teams and study participants.
A new study finds widespread exclusion of minorities in psychedelic research.
We’re seeing an explosion of medical research into psychedelics. Psilocybin, or shrooms, to treat major depressive disorder. Ayahuasca, a psychotropic plant medicine from the Amazon, and ibogaine, a potent hallucinogen from Africa, to treat addiction. LSD for anxiety.
Through this treatment plan, the patient was able to “reconceptualize her trauma” and “was able to move through difficult memories and emotions rather than letting them consume her,” explained U of O associate professor, Monnica Williams.
These substances are being touted as a game-changing intervention for mental health. But it’s not clear if their promise will be accessible to all.
2
A recent study found that even a single positive psychedelic experience may ease mental health symptoms associated with racial trauma experienced by Black, Indigenous, and people of color (BIPOC).
Society has started to become more accepting of our work and MAPS’ goal of mainstreaming psychedelic medicine seems closer than ever to being achieved,” explains MAPS Policy and Advocacy Director Natalie Ginsberg, M.S.W., in an interview with Jessica Semaan of Seismic Sisters.